Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adverum Biotechnlgs (NQ: ADVM )

0.6821 -0.0079 (-1.14%)
Streaming Delayed Price Updated: 2:10 PM EST, Jan 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,122,896
Open 0.7100
Bid (Size) 0.6814 (4)
Ask (Size) 0.6821 (1)
Prev. Close 0.6900
Today's Range 0.6790 - 0.7200
52wk Range 0.5310 - 1.820
Shares Outstanding 98,125,866
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock increased by 47.9% to $0.31 during Wednesday's pre-market session. The company's market cap stands at $11.8 million. 
Via Benzinga

Performance

YTD
+6.58%
+6.58%
1 Month
+6.58%
+6.58%
3 Month
-21.14%
-21.14%
6 Month
-50.57%
-50.57%
1 Year
-58.66%
-58.66%

More News

Read More
Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary
Via Benzinga
Adverum Commences Mid-Stage Chronic Eye Disorder Candidate Study
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Adverum Posts New Data From Wet AMD Gene Therapy Trial
Via Benzinga
Adverum Biotechnologies Cuts Workforce, Prioritizes ADVM-022
Via Benzinga
Adverum's Data at ASGCT Further Supports Phase 2 Development Plans For Wet-AMD Gene Therapy
Via Benzinga
Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday
Via Benzinga
The Daily Biotech Pulse: FDA Signs Off Cancer Therapy Trials For NexImmune, Omega Therapeutics, Endo To Develop Rare Hereditary Skin Disease Candidate
Via Benzinga
Adverum Bio Posts Additional Efficacy, Safety Data From ADVM-022 Gene Therapy In Wet AMD
Via Benzinga
Citigroup, Bank of America And 48 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Short Volatility Alert: Adverum Biotechnologies, Inc.
Via Benzinga
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study
Via Benzinga
3 Stocks Under $3 Insiders Are Aggressively Buying
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Adverum Moves Forward With IND Amendment For ADVM-022 Phase 2 Trial In Wet AMD
Via Benzinga
Adverum Outlines Development Plan For ADVM-022 Gene Therapy In Wet AMD
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.